secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001193125-25-075100
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties
--------------------------------------------------------------------------------

- Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.
- Also eligible for commercial milestones and mid-twenties% royalties on Japan NHI price.
- Sebetralstat is an investigational oral on-demand HAE treatment; could be first oral in Japan.
- Kaken will leverage regional expertise; KalVista aims for global commercial launches starting 2025.
- Orphan Drug Designation received from MHLW; NDA submitted in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525075100/0001193125-25-075100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525075100/d829369d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-075100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer